Vis enkel innførsel

dc.contributor.authorKilvær, Thomas Karsten
dc.contributor.authorValkov, Andrey Yurjevich
dc.contributor.authorSørbye, Sveinung Wergeland
dc.contributor.authorSmeland, Eivind
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorBusund, Lill-Tove
dc.contributor.authorDønnem, Tom
dc.date.accessioned2012-03-12T13:08:11Z
dc.date.available2012-03-12T13:08:11Z
dc.date.issued2011
dc.description.abstractNon-gastrointestinal stromal tumor soft-tissue sarcomas (non-GIST STSs) constitute a heterogeneous group of tumors with poor prognosis. Fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor-1 (FGFR-1), in close interplay with platelet-derived growth factor-B (PDGF-B) and vascular endothelial growth factor receptor-3 (VEGFR-3), are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients. Tumor samples from 108 non-GIST STS patients were obtained and tissue microarrays were constructed for each specimen. Immunohistochemistry was used to evaluate the expressions of FGF-2, FGFR-1, PDGF-B and VEGFR-3. In the multivariate analysis, high expression of FGF2 (P = 0.024, HR = 2.2, 95% CI 1.1-4.4) and the co-expressions of FGF2 & PDGF-B (overall; P = 0.007, intermediate; P = 0.013, HR = 3.6, 95% CI = 1.3-9.7, high; P = 0.002, HR = 6.0, 95% CI = 2.0-18.1) and FGF2 & VEGFR-3 (overall; P = 0.050, intermediate; P = 0.058, HR = 2.0, 95% CI = 0.98-4.1, high; P = 0.028, HR = 2.6, 95% CI = 1.1-6.0) were significant independent prognostic indicators of poor disease-specific survival. FGF2, alone or in co-expression with PDGF-B and VEGFR-3, is a significant independent negative prognosticator in widely resected non-GIST STS patients.en
dc.identifier.citationJournal of Translational Medicine (2011), 9:104en
dc.identifier.cristinIDFRIDAID 848953
dc.identifier.doidoi: 10.1186/1479-5876-9-104
dc.identifier.issn1479-5876
dc.identifier.urihttps://hdl.handle.net/10037/3934
dc.identifier.urnURN:NBN:no-uit_munin_3656
dc.language.isoengen
dc.publisherBioMed Centralen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titleFibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patientsen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel